Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

The trial enrolled more than 40,800 adults 50 and older from 11 countries.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

CDC advisory committee recommends thimerosal-free influenza vaccines for all adults and children, despite claims that the ...